|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Major Depressive Disorder - Gaining traction among physicians is crucial in an SSRI-dominated market
Datamonitor, Dec 2010, Pages: 198
Introduction
Prescribing trends reveal that the MDD market is receptive to alternative modes of actions at later lines of therapy, while traditional classes dominate earlier lines. Favorable physician perception is crucial in order to maximize uptake into the market, as demonstrated by recent antipsychotic labeling expansions. The clear demonstration of efficacy and tolerability is therefore paramount.
Features and benefits
- Forecasts of major depressive disorder patient population numbers in the seven major markets based on a comprehensive epidemiological review.
- Estimated presentation and diagnosis rates, care pathway, and segmentation of depression cases by disease severity, age, and gender.
- In-depth analysis of treatment patterns and regimens prescribed for MDD by antidepressant class and line of therapy.
- Analysis of 10 key brands, including SSRIs, SNRIs, antipsychotics, and novel antidepressants, based upon physician perception and therapeutic role.
- Detailed review of patient outcomes, including progression through lines of therapy, treatment-resistant depression, relapse, and compliance.
Highlights
Although The survey suggests treatment decisions are usually made by psychiatrists, interviewed KOLs suggest that PCPs are actively managing the majority of MDD patients. Understanding the physician type that is most involved with depressed patients is important in tailoring a strong marketing message to a target audience.SSRI usage is by far the highest at first line and decreases at later lines of therapy, in direct contrast all other classes of drugs for MDD.
Lexapro is widely perceived by psychiatrists to be the gold standard, possessing the best overall efficacy and tolerability. These were rated as the two most important clinical attributes by psychiatrists.Abilify, being the first antipsychotic to be granted FDA approval for MDD, is highly thought of by US psychiatrists, while EU psychiatrists tend to favor Seroquel, which became the first EC-approved antipsychotic. Physician perception is swayed by regulatory approval, which allows specific marketing and removes barriers to off-label prescription.
Your key questions answered
- How large is the diagnosed major depressive disorder patient population? How do these patients progress through the care pathway?
- Which classes of drugs are prescribed the most and what is their most common therapeutic role? How does this change at second- and third-line therapy?
- Which factors influence psychiatrists' prescribing decisions the most? How can a product best differentiate itself from the competition?
- How have the recent regulatory approvals of Abilify and Seroquel XR influenced the perceptions of psychiatrists?
|
|
|
|
